Roch Doliveux - Stryker Independent Director
| SYK Stock | EUR 312.70 3.20 1.03% |
Director
Dr. Roch Doliveux, DVM, is Independent Director of the Company, since June 21, 2010. He is a Chairman of the Board, Pierre Fabre SA, a global dermocosmetics and healthcare company. Chairman of GLG Institute, a community of senior executives for experience sharing and learning. Director of UCB, a global biopharmaceutical company, where he was Chief Executive Officer for 10 years. He is also Chairman of the Board of the Vlerick Business School, a top100 business school in the world based in Belgium and of the Caring Entrepreneurship Fund, a philanthropic organization to help entrepreneurs start their own businesses in healthcare since 2010.
| Age | 62 |
| Tenure | 14 years |
| Phone | 269 385 2600 |
| Web | https://www.stryker.com |
Stryker Management Efficiency
The company has return on total asset (ROA) of 0.0618 % which means that it generated a profit of $0.0618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0618 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Silvernail, Independent Director | ||
| Fink, Vice President Global Human Resources | ||
| Sherilyn McCoy, Independent Director | ||
| Robert Cohen, CTO Replacement | ||
| Ronda Stryker, Independent Director | ||
| Curtis Hall, Chief Legal Officer | ||
| Spencer Stiles, Group Spine | ||
| Andrew Pierce, Group Neurotechnology | ||
| William Berry, Principal Accounting Officer, Vice President Corporate Controller | ||
| Allan Golston, Independent Director | ||
| Katherine Owen, Vice President - Strategy and Investor Relations | ||
| Graham Mclean, President Asia-Pacific | ||
| Louise Francesconi, Independent Director | ||
| Kevin Lobo, President CEO, Director | ||
| Jason Beach, VP Relations | ||
| Roch Doliveux, Independent Director | ||
| David Floyd, Group President - Orthopaedics | ||
| William Jellison, CFO, Vice President | ||
| Yin Becker, Vice President of Communication and Public Affairs | ||
| Timothy Scannell, Group President - MedSurg and Neurotechnology | ||
| William Parfet, Non-Executive Independent Chairman of the Board | ||
| Robert Fletcher, Vice President Chief Legal Officer | ||
| Dean Bergy, Vice President Corporate Secretary | ||
| Rajeev Suri, Independent Director | ||
| Alan Douville, Chief VP | ||
| Glenn Boehnlein, CFO, Vice President | ||
| Viju Menon, Group President - Global Quality and Business Operations | ||
| Lonny Carpenter, Group President - Global Quality and Operations | ||
| Bijoy Sagar, CIO, Vice President | ||
| Mary Brainerd, Director | ||
| Srikant Datar, Independent Director | ||
| Michael Hutchinson, General Counsel | ||
| Bronwen Taylor, Vice President - Compliance and Risk Management | ||
| Howard Cox, Independent Director | ||
| Steven Benscoter, Vice President - Human Resources | ||
| Kathryn Fink, Chief Human Resource Officer, Vice President | ||
| Scott Bruder, Vice President Chief Medical and Scientific Officer |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0618 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 101.82 B | |||
| Shares Outstanding | 378.83 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 80.48 % | |||
| Price To Earning | 20.44 X | |||
| Price To Book | 5.77 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Stryker in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Stryker's short interest history, or implied volatility extrapolated from Stryker options trading.
Currently Active Assets on Macroaxis
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Stryker Stock please use our How to Invest in Stryker guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Stryker Stock analysis
When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |